The MYG1 Knockout TE1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the MYG1 gene in the human TE1 esophageal epithelial cell line. This polyclonal format comprises a heterogeneous pool of cells with targeted gene disruptions, providing a robust loss-of-function model while avoiding clonal artifacts. The use of CRISPR/Cas9-mediated gene disruption ensures efficient ablation of MYG1 expression without the need for single-cell cloning, preserving population diversity. Researchers can employ this model to investigate MYG1-dependent mitochondrial and oncogenic processes.
The TE1 cell line is derived from a human esophageal squamous cell carcinoma (ESCC), an aggressive epithelial malignancy with limited treatment options. TE1 cells exhibit characteristic epithelial morphology and retain key genomic alterations and signaling aberrations found in ESCC. As a widely used in vitro model, TE1 cells enable dissection of molecular mechanisms driving esophageal carcinogenesis, drug resistance, and metastatic progression. The MYG1 knockout in this clinically relevant background provides a powerful tool to study mitochondrial contributions to ESCC biology.
MYG1 encodes a mitochondrial protein that functions as an assembly factor for the mitochondrial ribosome (mitoribosome). Its expression is transcriptionally regulated by PGC-1?? (PPARGC1A) and NRF1, master controllers of mitochondrial biogenesis. MYG1 interacts with mitochondrial ribosomal proteins (MRPLs) and other assembly factors to facilitate proper mitoribosome formation, which is essential for translation of mitochondrial-encoded OXPHOS subunits, including MT-CO1 and MT-ND1. Dysfunction of MYG1 thus disrupts mitochondrial protein synthesis and downstream respiratory chain activity.
In TE1 esophageal cancer cells, CRISPR/Cas9-mediated knockout of MYG1 impairs mitoribosome assembly, leading to reduced production of OXPHOS complex components and compromised mitochondrial respiration. This defect is anticipated to curtail cell proliferation and alter cellular stress responses, underscoring the importance of mitochondrial translation in cancer cell fitness. The MYG1 knockout model therefore offers a physiologically relevant system to explore how mitochondrial gene expression interfaces with oncogenic signaling and metabolic reprogramming in ESCC.
The MYG1 Knockout TE1 Polyclonal Cells are suited for a wide range of experimental assays. Key techniques include Western blotting to assess OXPHOS subunit abundance, RT-qPCR for mitochondrial transcript levels, Seahorse analysis for real-time respiratory function, MTT assays for proliferation, and Annexin V staining for apoptosis detection. These cells enable in-depth functional studies of MYG1 in esophageal cancer, mechanistic investigations of mitochondrial translation in oncology, and drug screening campaigns targeting mitochondrial vulnerabilities. For technical inquiries or ordering information, please contact Ascent Research.
